BioCentury | Mar 4, 2013
Finance

EdRIP's exit mantra

...for cancer Feb 2005 - $18M series B Jun 2006 - $32M IPO on Euronext Novagali Pharma S.A....
BioCentury | Mar 5, 2012
Finance

Rothschild's bigger war chest

...be able to continue that trend," he added. The most recent sale was ophthalmic company Novagali Pharma S.A....
BioCentury | Jan 9, 2012
Finance

PDUFAs produce yawns

Stephen Hansen Senior Writer There are more than twice as many PDUFA dates this year than last - at least 40 vs. 17 - but only a handful of potential approvals are drumming up interest among buysiders....
BioCentury | Jan 2, 2012
Company News

Novagali, Santen deal

...Santen completed its mandatory tender offer to acquire the remaining shares of fellow ophthalmic company Novagali...
...the remaining shares at €6.25 per share on Jan 6, at which point trading in Novagali...
...of Novagali shares upon completion of the mandatory tender offer (see BioCentury, Oct. 17, 2011). Novagali Pharma S.A....
BioCentury | Oct 17, 2011
Company News

Novagali, Santen Pharmaceuticals Co. Ltd. deal

...Santen acquired a 50.55% stake in Novagali for €6.15 per share through the purchase of 8.2...
...mandatory tender offer to acquire the remaining shares. If Santen holds at least 95% of Novagali...
...an additional €0.10 per share to shareholders who tendered their shares (see BioCentury, Oct. 3). Novagali Pharma S.A....
BioCentury | Oct 3, 2011
Finance

Highlights of weekly biotech stock moves

...through the sale of 38.5 million shares at C$0.65 per share in a private placement. Novagali Pharma S.A....
BioCentury | Oct 3, 2011
Company News

Novagali, Santen deal

...Santen will acquire fellow ophthalmic company Novagali for €6.15 per share, or about €100 million ($134.2...
...71% premium to Novagali's close of €3.59 on Sept. 27, before the deal was announced. Novagali...
...markets Cationorm active-free ophthalmic cationic emulsion for dry eye, reported 1H11 sales of €369,000 ($534,644). Novagali's...
BioCentury | Sep 29, 2011
Company News

Santen to acquire Novagali

...Santen Pharmaceutical Co. Ltd. (Tokyo:4536; Osaka:4536) will acquire fellow ophthalmic company Novagali Pharma S.A. (Euronext:NOVA) for EUR 6.15...
...71% premium to Novagali's close of EUR 3.59 on Tuesday, before the deal was announced. Novagali...
...Cationorm active-free ophthalmic cationic emulsion for dry eye, reported 1H11 sales of EUR 369,000 ($534,644). Novagali's...
BioCentury | Sep 12, 2011
Clinical News

Catioprost: Phase II data

...patients receiving Catioprost experienced worsening of their conjunctival hyperemia vs. Travatan Z (26% vs. 43%). Novagali...
...October. The Alcon Inc. division of Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) markets Travatan Z. Novagali Pharma S.A....
BioCentury | Apr 25, 2011
Clinical News

Catioprost: Completed Phase II enrollment

...travoprost. The Alcon Inc. division of Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) markets Travatan Z. Novagali Pharma S.A....
Items per page:
1 - 10 of 63
BioCentury | Mar 4, 2013
Finance

EdRIP's exit mantra

...for cancer Feb 2005 - $18M series B Jun 2006 - $32M IPO on Euronext Novagali Pharma S.A....
BioCentury | Mar 5, 2012
Finance

Rothschild's bigger war chest

...be able to continue that trend," he added. The most recent sale was ophthalmic company Novagali Pharma S.A....
BioCentury | Jan 9, 2012
Finance

PDUFAs produce yawns

Stephen Hansen Senior Writer There are more than twice as many PDUFA dates this year than last - at least 40 vs. 17 - but only a handful of potential approvals are drumming up interest among buysiders....
BioCentury | Jan 2, 2012
Company News

Novagali, Santen deal

...Santen completed its mandatory tender offer to acquire the remaining shares of fellow ophthalmic company Novagali...
...the remaining shares at €6.25 per share on Jan 6, at which point trading in Novagali...
...of Novagali shares upon completion of the mandatory tender offer (see BioCentury, Oct. 17, 2011). Novagali Pharma S.A....
BioCentury | Oct 17, 2011
Company News

Novagali, Santen Pharmaceuticals Co. Ltd. deal

...Santen acquired a 50.55% stake in Novagali for €6.15 per share through the purchase of 8.2...
...mandatory tender offer to acquire the remaining shares. If Santen holds at least 95% of Novagali...
...an additional €0.10 per share to shareholders who tendered their shares (see BioCentury, Oct. 3). Novagali Pharma S.A....
BioCentury | Oct 3, 2011
Finance

Highlights of weekly biotech stock moves

...through the sale of 38.5 million shares at C$0.65 per share in a private placement. Novagali Pharma S.A....
BioCentury | Oct 3, 2011
Company News

Novagali, Santen deal

...Santen will acquire fellow ophthalmic company Novagali for €6.15 per share, or about €100 million ($134.2...
...71% premium to Novagali's close of €3.59 on Sept. 27, before the deal was announced. Novagali...
...markets Cationorm active-free ophthalmic cationic emulsion for dry eye, reported 1H11 sales of €369,000 ($534,644). Novagali's...
BioCentury | Sep 29, 2011
Company News

Santen to acquire Novagali

...Santen Pharmaceutical Co. Ltd. (Tokyo:4536; Osaka:4536) will acquire fellow ophthalmic company Novagali Pharma S.A. (Euronext:NOVA) for EUR 6.15...
...71% premium to Novagali's close of EUR 3.59 on Tuesday, before the deal was announced. Novagali...
...Cationorm active-free ophthalmic cationic emulsion for dry eye, reported 1H11 sales of EUR 369,000 ($534,644). Novagali's...
BioCentury | Sep 12, 2011
Clinical News

Catioprost: Phase II data

...patients receiving Catioprost experienced worsening of their conjunctival hyperemia vs. Travatan Z (26% vs. 43%). Novagali...
...October. The Alcon Inc. division of Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) markets Travatan Z. Novagali Pharma S.A....
BioCentury | Apr 25, 2011
Clinical News

Catioprost: Completed Phase II enrollment

...travoprost. The Alcon Inc. division of Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) markets Travatan Z. Novagali Pharma S.A....
Items per page:
1 - 10 of 63